NCT02924337View on ClinicalTrials.gov

Effect of Imeglimin on QT/QTc Intervals in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Qt Interval, Variation in
Interventions
DRUG

Placebo

DRUG

Imeglimin

DRUG

Moxifloxacin

Trial Locations (1)

Unknown

Hammersmith Medicines Research (HMR), London

Sponsors

Lead Sponsor

Poxel SA
All Listed Sponsors
lead

Poxel SA

INDUSTRY

NCT02924337 - Effect of Imeglimin on QT/QTc Intervals in Healthy Subjects | Biotech Hunter | Biotech Hunter